Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus daratumumab with or without low-dose cyclophosphamide in relapsed/refractory multiple myeloma
NL-OMON47546Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Feb 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, daratumumab and cyclophosphamide in multiple myeloma (MM) (2 arms), sponsored by Vrije University Medical Center. Primary endpoints: Regimen selection based on safety and efficacy and Overall response rate. Started Feb 2018; status: active, not recruiting.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON47546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47546.